Objective PneumoSIP project aims to be the first fully automated device in the POC market for the fast quantitative aetiological diagnose of Community-Acquired Pneumonia (CAP) also analysing antibiotic resistances to enable the most appropriate treatment for each infected patient.CAP is known to affect about 1/1,000 of the adult population per year, being even higher in the elderly and children populations. It is the fourth case of death in the world, and the leading cause of death in child population under 5 years old. The causal relationship between pathogens and pneumonia has been clearly established, being Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and the respiratory syncytial virus (RSV) the main pathogens responsible for CAP in Europe. Antibiotic therapy is the mainstream treatment for CAP, and the appropriate treatment involves starting empiric antibiotics administration within 8 hours of hospital arrival. Given this time constrain, traditional methods for diagnosing the aetiology of CAP have been discarded for CAP guidelines due to the slowness in sample to results. Another complication is that S. pneumoniae is a common colonizer of the nasopharynx (up to 70% of healthy population acts as a host), making the simple detection of the bacteria a useless diagnostic method. Thus, clinicians need rapid and accurate quantitative tests capable of identifying infectious agents and their potential antibiotic resistances. Therefore, PneumoSIP project aims to be a compact Respiratory Infectious Diseases diagnostic device providing fast quantitative identification of pathogens involved in CAP, enabling faster and more specific treatments. PneumoSIP seeks to combine laboratory standard precision with the simplicity required for POC applications. The market for PneumoSIP system is the POC market, concretely the Infectious Disease POC testing segment. The POCT segment was valued at $415.4 million in 2012 where Pneumosip will greatly impact. Fields of science medical and health sciencesclinical medicinepneumologynatural sciencescomputer and information sciencessoftwaremedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-2-2015 Funding Scheme SME-2 - SME instrument phase 2 Coordinator LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP Net EU contribution € 3 389 912,50 Address CALLE CERVANTES 40 - 3P - PC 50006 ZARAGOZA Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste Aragón Zaragoza Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 389 912,50
